CarlDMorrisonMD

Summary

• As a board-certified pathologist with interests in both surgical and molecular pathology I regularly participate in the sign out of surgical pathology reports and advanced diagnostic laboratory tests. From a surgical pathology perspective my interest has always been in bone and soft tissue. As a molecular pathologist my interest has extended past single analyte tests to advanced diagnostic testing with an emphasis on next generation sequencing. More recently have focused on the application of this technology in the immune-oncology space with the development of cutting edge assays to predict response to checkpoint inhibitors and guide choice of combination immunotherapy (i.e. precision immunotherapy). On a national basis, as the founder of OmniSeq Inc as a national provider of genomic and immune-related advanced diagnostic assays. Routinely speak at immunotherapy conferences about prediction of response to checkpoint inhibitors and guide choice of combination immunotherapy.